The OEV-124 study is a sequel to the already successful phase I/II trial in a Bangladeshi study encompassing 495 participants as young as 6 months old. The Zambian trial will further establish the exact safe and immunogenic dose of the vaccine in young children as well as to explore the potential benefits of a third booster dose.

The study will be conducted in healthy adults (n = 40) and children (n = 206) 6-23 months old.

This study is co funded by  the EU Research and Innovation Framework Program, Horizon 2020 through the European and Developing Countries Clinical Trials Partnership (EDCTP) organization.